{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T17:22:54Z","timestamp":1791566574351,"version":"4.3.4"},"reference-count":28,"publisher":"Wiley","issue":"23","license":[{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:00:00Z","timestamp":1764201600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2022LSW001"],"award-info":[{"award-number":["ZR2022LSW001"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y\u20102024AZ NSCLC MS\u20100100"],"award-info":[{"award-number":["Y\u20102024AZ NSCLC MS\u20100100"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373044"],"award-info":[{"award-number":["82373044"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Medicine"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Epidermal growth factor receptor (EGFR)\u2013specific tyrosine kinase inhibitors show less efficacy against the EGFR L858R mutation than EGFR 19del, but no current head\u2010to\u2010head clinical trials have been performed comparing the efficacy of almonertinib and osimertinib. Therefore, our study compared the efficacy of these drugs against the EGFR L858R mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>A total of 200 patients with non\u2010small cell lung cancer harboring the EGFR L858R mutation were enrolled. Among these patients, 121 received 80\u2009mg of osimertinib, while the other 79 received 110\u2009mg of almonertinib once daily. The primary end point was progression\u2010free survival (PFS). The secondary end points were continued response rate and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median PFS was 18.5\u2009months (95% confidence interval [CI] 16.1\u201322.5) for osimertinib and 19.4\u2009months (95% CI 13.8\u2013NA) for almonertinib, with a hazard ratio (HR) of 0.92 (95% CI 0.62\u20131.73),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.69. Forest plots of subgroup analyses showed no significant difference in the median PFS between the almonertinib and osimertinib groups across the subgroups. Osimertinib and almonertinib demonstrated good efficacy in the treatment of patients with brain metastases. The median PFS was 18.6\u2009months (95% CI 15.6\u201322.8) for patients with brain metastases and 17.1\u2009months (95% CI 14.1\u201328.6) for those without brain metastases,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.89. Patients with programmed cell death ligand 1 (PD\u2010L1) expression between 1% and 49% and PD\u2010L1 expression &lt;\u20091% showed no significant differences for their median PFS. The continued response rates between almonertinib and osimertinib were comparable. The differences between almonertinib and osimertinib were minimal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Both almonertinib and osimertinib demonstrated good efficacy in patients with brain metastases, and PD\u2010L1 expression was not associated with the prognosis of EGFR L858R mutant NSCLC. Finally, no significant difference between osimertinib and almonertinib for the treatment of patients with EGFR L858R mutations was observed. Both options remain viable for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cam4.71422","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:04:47Z","timestamp":1764266687000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of Almonertinib Versus Osimertinib as the First\u2010Line Treatment for Non\u2010Small Cell Lung Cancer With\n                    <scp>EGFR L858R<\/scp>\n                    Mutation and Prognostic Analysis: A Retrospective Comparative Cohort Study"],"prefix":"10.1002","volume":"14","author":[{"given":"Xiujing","family":"Yao","sequence":"first","affiliation":[{"name":"School of Clinical Medicine Shandong Second Medical University  Weifang Shandong China"},{"name":"Department of Respiratory Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences  Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Li","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine Shandong Second Medical University  Weifang Shandong China"},{"name":"Department of Respiratory Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences  Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[{"name":"Department of Respiratory Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences  Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Respiratory Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences  Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4665-8900","authenticated-orcid":false,"given":"Yintao","family":"Li","sequence":"additional","affiliation":[{"name":"School of Clinical Medicine Shandong Second Medical University  Weifang Shandong China"},{"name":"Department of Respiratory Oncology, Shandong Cancer Hospital and Institute Shandong First Medical University and Shandong Academy of Medical Sciences  Jinan Shandong China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21820"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35128"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2024.07.001"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159\u20108290.CD\u201017\u20100368"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.06.019"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7576"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2024.09.005"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010015\u20100533\u20104"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201021\u20101034"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201016\u20100399"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13951"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.5582\/ddt.2021.01013"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpt.2022.10.003"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02641"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.001"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.11.028"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759\u20107714.12568"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S255967"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2010020\u201003296\u20106"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759\u20107714.12343"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l5460"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211020798"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095\u20103941.2018.0223"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2021.03.004"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759\u20107714.15021"}],"container-title":["Cancer Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71422","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cam4.71422","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cam4.71422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:27:47Z","timestamp":1771331267000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cam4.71422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,27]]},"references-count":28,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1002\/cam4.71422"],"URL":"https:\/\/doi.org\/10.1002\/cam4.71422","archive":["Portico"],"relation":{},"ISSN":["2045-7634","2045-7634"],"issn-type":[{"value":"2045-7634","type":"print"},{"value":"2045-7634","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,27]]},"assertion":[{"value":"2025-03-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e71422"}}